Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lilly and Daiichi win European approval for blood thinner drug
The approval follows a positive opinion adopted by the Committee for Medicinal Products for Human Use of the European Medicines Agency in December 2008. Daiichi Sankyo Company and
The approval follows a positive opinion adopted by the Committee for Medicinal Products for Human Use of the European Medicines Agency in December 2008. Daiichi Sankyo Company and
Additionally, Abbott announced an agreement to open a new nutrition science research and development center in Singapore, where its scientists will focus on clinical trials and development of
The Phase II trial is an active (enoxaparin)-controlled, dose-escalating, multicenter, prospective, randomized, open-label trial evaluating TB-402 for the prophylaxis of deep vein thrombosis (DVT) after knee surgery. The
Matrix’s version of this product is heat-stable and affordable, making it practical for distribution and use in warm climates. Lopinavir/ritonavir tablets are the generic version of Abbott Laboratories’s
According to the company, the GemStar SP infusion system is designed to help caregivers incorporate patient safety best practices right at the patient’s bedside. The company said that
Following the restructuring, Trubion will continue to invest in the development of its proprietary program, TRU-016, and the efficient and timely advancement of select preclinical assets that it
As Arca’s CFO and COO, Ms Falberg will be responsible for the company’s accounting, corporate finance, financial planning, treasury and other corporate functions. Ms Falberg will report to
Mr Thurman has been serving as chairman of the board since June 2008 and interim president and CEO since January 2009. Mr Thurman most recently served as chairman
Sales were strong throughout the year. To March 2008 turnover increased 10.9% compared with the previous year, while in the second quarter this increase was 16.8%. The third
Since joining Sanofi-Aventis in the UK in 1994, Mr Steve has achieved significant results for the company in a number of positions including marketing director and business unit